Results 41 to 50 of about 4,961 (248)
Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke [PDF]
, 2017 Objective: To describe the benefits of reversal of the anticoagulation effects of dabigatran etexilate in patients requiring urgent surgery or thrombolysis for ischaemic stroke. Materials and methods: Four patients, treated with dabigatran etexilate and
Fredrik von Wowern +2 more
openalex +4 more sources
Idarucizumab in High-risk Thoracic Surgery
International Journal of Organ Transplantation Medicine, 2018 Direct oral anticoagulants have suggested a favorable profile compared with vitamin K antagonists. However, the lack of treatment to reverse the effect of direct oral anticoagulants has limited its use in some patients who require rapid reversal of ...
R L�pez Vilella +5 more
doaj +2 more sources
Idarucizumab for Reversion of Anticoagulant Effect in Daily Practice [PDF]
Thrombosis and Haemostasis, 2019 Background and Purpose— We compared the 1-year safety and effectiveness of rivaroxaban 15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with nonvalvular atrial fibrillation. Methods— New user cohort study of patients dispensed R15 or R20 versus VKA in 2013 or 2014 for nonvalvular atrial fibrillation, followed 1 year in
Patrick Blin +9 more
openalex +5 more sources
The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
Scientific Reports, 2021 Dabigatran interferes with many coagulation tests. To overcome this obstacle the use of idarucizumab as an in vitro antidote to dabigatran has been proposed.
Mojca Božič Mijovski +4 more
doaj +1 more source
Left atrial intramural hematoma following right atrial catheter ablation: A rare case involving coronary sinus injury. [PDF]
J ArrhythmLeft atrial intramural hematoma (LAIH) is an exceedingly rare complication that occurs following catheter ablation in the right atrium. The present case is the first to implicate coronary sinus catheter manipulation—rather than left atrial intervention—as a potential mechanism of LAIH.
Hatsuno M +4 more
europepmc +2 more sources
Intravenous thrombolysis following dabigatran reversal in a patient with acute embolic stroke after atrial fibrillation ablation. [PDF]
J ArrhythmThis case demonstrated the feasibility of administering emergent intravenous thrombolysis followed by Dabigatran reversal with idarucizumab in a patient who underwent atrial fibrillation ablation. The consideration of transitioning anticoagulant therapy to dabigatran for scheduled AF ablation in patients at high risk of stroke should be carefully ...
Chen YS, Lin CY.
europepmc +2 more sources
Neurologia i Neurochirurgia Polska, 2023 INTRODUCTION Our study analysed the safety and effectiveness of idarucizumab in enabling intravenous thrombolysis (IVT) in dabigatran-treated patients with acute ischaemic stroke (AIS).
E. Włodarczyk +3 more
semanticscholar +1 more source
Cardiology and Therapy, 2020 Introduction Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016.
Masahiro Yasaka +7 more
doaj +1 more source
No Benefit for Idarucizumab [PDF]
Deutsches Ärzteblatt international, 2016 The review article by Lange et al. on the management of anticoagulation in the setting of endoscopic interventions provides helpful advice and pointers for routine clinical practice (1). Their assessment clashes with the available evidence in one single issue: idarucizumab has thus far not been shown to offer any benefit in terms of the safe ...
openaire +3 more sources
How we treat bleeding associated with direct oral anticoagulants [PDF]
, 2016 Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo +4 more
core +1 more source